CU23713B7 - Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen - Google Patents
Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienenInfo
- Publication number
- CU23713B7 CU23713B7 CU20040029A CU20040029A CU23713B7 CU 23713 B7 CU23713 B7 CU 23713B7 CU 20040029 A CU20040029 A CU 20040029A CU 20040029 A CU20040029 A CU 20040029A CU 23713 B7 CU23713 B7 CU 23713B7
- Authority
- CU
- Cuba
- Prior art keywords
- degrees
- acid salt
- anhyding
- pirrol
- indolinone
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 2
- QNDPUZFBWUBSNH-UHFFFAOYSA-I magic acid Chemical class OS(F)(=O)=O.F[Sb](F)(F)(F)F QNDPUZFBWUBSNH-UHFFFAOYSA-I 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 3
- 235000011090 malic acid Nutrition 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 229940099690 malic acid Drugs 0.000 abstract 2
- 239000001630 malic acid Substances 0.000 abstract 2
- WINHZLLDWRZWRT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(C=C2C3=CC(F)=CC=C3NC2=O)=C1C WINHZLLDWRZWRT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940116298 l- malic acid Drugs 0.000 abstract 1
- 150000004701 malic acid derivatives Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
Cristales anhidros de una sal de ácido málico de un compuesto que tiene la estructura: ESPACIO PARA FÓRMULA donde el cristal es preferentemente ácido málico es ácido L-málico o una sal del ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, y tiene picos de difracción característicos a aproximadamente 13,2 y 24,2 grados dos teta (forma cristalina I) en un patrón de difracción de polvo por rayos X, preferentemente a aproximadamente 13,2, 19,4, 24,2 y 25,5 grados dos teta, o picos de difracción característicos a aproximadamente 3,0 y 27,2 grados dos teta en un patrón de difracción del polvo por rayos X, preferentemenete a aproximadamente 13,2, 19,4, 24,2 y 25,5 grados dos teta (forma cristalina II) en un patrón de difracción del polvo por rayos X, preferentemente a aproximadamente 3,0, 12,1, 14,5 y 27,7 grados teta; métodos para preparar dichos cristales anhidros; y composición que los comprende.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31235301P | 2001-08-15 | 2001-08-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20040029A7 CU20040029A7 (es) | 2008-03-14 |
| CU23713B7 true CU23713B7 (es) | 2011-10-05 |
Family
ID=23211067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20040029A CU23713B7 (es) | 2001-08-15 | 2004-02-12 | Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen |
Country Status (42)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20040112B1 (en) | 2001-08-15 | 2012-03-31 | Pharmacia & Upjohn Company | Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
| HN2003000272A (es) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
| BRPI0415022A (pt) * | 2003-10-02 | 2006-11-28 | Pharmacia & Upjohn Co Llc | sais e polimorfos de um composto de indolinona substituìda com pirrol |
| US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
| WO2006019835A1 (en) * | 2004-07-22 | 2006-02-23 | Eli Lilly And Company | A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt |
| CA2603445A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| ES2328407T3 (es) * | 2005-09-19 | 2009-11-12 | Pfizer Products Incorporated | Formas salinas solidas de una 2-indolinona sustituida con pirrol. |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| EP2220072A2 (en) | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| EP2229380A1 (en) * | 2007-12-12 | 2010-09-22 | Medichem, S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
| EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| CN101983195A (zh) * | 2008-02-21 | 2011-03-02 | 基因里克斯(英国)有限公司 | 新型多晶型物及其制备方法 |
| EP2098521A1 (en) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
| JP2011516488A (ja) * | 2008-03-31 | 2011-05-26 | テバ ファーマシューティカル インダストリーズ リミティド | スニチニブ及びその塩の調製方法 |
| CA2720943A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| RU2468022C2 (ru) * | 2008-05-23 | 2012-11-27 | Шанхай Инститьют Оф Фармасьютикал Индастри | Производные дигидроиндолона |
| AR072117A1 (es) * | 2008-06-13 | 2010-08-04 | Medichem Sa | Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende. |
| EP2138167A1 (en) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| WO2009156837A2 (en) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
| US20110257237A1 (en) * | 2008-07-10 | 2011-10-20 | Generics [Uk] Limited | Process for the preparation of crystalline forms of sunitinib malate |
| CN102164913A (zh) * | 2008-07-24 | 2011-08-24 | 麦迪凯姆股份公司 | 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式 |
| WO2010011834A2 (en) * | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| CN102197034A (zh) * | 2008-08-25 | 2011-09-21 | 基因里克斯(英国)有限公司 | 舒尼替尼的新型多晶型物及其制备方法 |
| CA2734965A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel crystalline form and processes for its preparation |
| AR073807A1 (es) * | 2008-10-10 | 2010-12-01 | Medichem Sa | Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria. |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2373643A4 (en) * | 2009-01-02 | 2013-08-07 | Hetero Research Foundation | NEW SUNITINIB MALATE POLYMORPHS |
| KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
| WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
| CA2774634A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Salts of sunitinib |
| WO2011058521A2 (en) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
| EP2501694A1 (en) | 2009-11-19 | 2012-09-26 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib |
| EP2528913A1 (en) | 2010-01-29 | 2012-12-05 | Ranbaxy Laboratories Limited | Crystalline forms of l-malic acid salt of sunitinib |
| WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
| WO2011104555A2 (en) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
| EP2542550A1 (en) | 2010-03-04 | 2013-01-09 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
| WO2011114246A1 (en) | 2010-03-18 | 2011-09-22 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
| WO2011128699A2 (en) | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| WO2013140232A1 (en) | 2012-03-23 | 2013-09-26 | Laurus Labs Private Limited | An improved process for the preparation of sunitinib and its acid addition salts thereof |
| PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
| SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9604968B2 (en) | 2013-10-18 | 2017-03-28 | Sun Pharmaceutical Industries Limited | Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation |
| CA2838585A1 (en) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | An ascorbic acid salt of sunitinib |
| WO2015063647A1 (en) | 2013-11-01 | 2015-05-07 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| CN104693187A (zh) * | 2013-12-10 | 2015-06-10 | 安杰世纪生物科技（北京）有限公司 | 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法 |
| CN104744442B (zh) * | 2013-12-25 | 2019-05-28 | 江苏豪森药业集团有限公司 | 苹果酸舒尼替尼的制备方法 |
| RU2567535C1 (ru) * | 2014-10-01 | 2015-11-10 | Олег Ростиславович Михайлов | КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ |
| CN105712979A (zh) * | 2014-12-05 | 2016-06-29 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种苹果酸舒尼替尼晶型ⅰ的制备方法 |
| EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
| JP2022529290A (ja) * | 2019-04-18 | 2022-06-20 | メーター ヘルス インコーポレイテッド | 呼吸性不整脈を処置するための方法および組成物 |
| EP3958845A1 (en) | 2019-04-25 | 2022-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
| JP7633786B2 (ja) * | 2020-09-18 | 2025-02-20 | 日本化薬株式会社 | スニチニブリンゴ酸塩を有効成分とする医薬錠剤 |
| KR20240025990A (ko) | 2022-08-19 | 2024-02-27 | 주식회사 스카이테라퓨틱스 | 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0179053B1 (ko) | 1990-10-15 | 1999-03-20 | 알렌 제이.스피겔 | 인돌 유도체 |
| IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| CZ282060B6 (cs) | 1992-06-05 | 1997-05-14 | Merck Sharp And Dohme Limited | Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby |
| AU694419B2 (en) | 1993-03-12 | 1998-07-23 | Zoetis P&U Llc | Crystalline ceftiofur free acid |
| US6329364B1 (en) | 1994-08-31 | 2001-12-11 | Eli Lilly And Company | Crystalline form of dihydro-2,3-benzodiazepine derivative |
| DE19503966C2 (de) | 1995-02-07 | 1998-07-02 | Mack Chem Pharm | Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung |
| US5597663A (en) * | 1995-05-30 | 1997-01-28 | Motorola, Inc. | Low temperature molten lithium salt electrolytes for electrochemical cells |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5673451A (en) * | 1995-07-06 | 1997-10-07 | Moore; James R. | Instructional toothbrush |
| US20020038021A1 (en) | 1995-12-11 | 2002-03-28 | Barton Kathleen P. | Eplerenone crystalline form exhibiting enhanced dissolution rate |
| US20020045746A1 (en) | 1995-12-11 | 2002-04-18 | Barton Kathleen P. | Eplerenone crystalline form |
| US6066647A (en) | 1996-07-29 | 2000-05-23 | Pfizer Inc. | Zwitterionic forms of trovafloxacin |
| DE69717281T2 (de) | 1996-08-14 | 2003-09-04 | G.D. Searle & Co., Chicago | Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid |
| KR100530601B1 (ko) | 1996-12-25 | 2005-11-23 | 니폰 가야꾸 가부시끼가이샤 | 시스플라틴 미분말 및 그의 제조방법 |
| US5777185A (en) * | 1997-09-09 | 1998-07-07 | Laroche Industries Inc. | Production of organic fluorine compounds |
| US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| US6012678A (en) * | 1998-01-26 | 2000-01-11 | The Boeing Company | Galley vacuum waste disposal system |
| EP1956015B2 (en) | 1998-06-19 | 2018-11-14 | Teijin Limited | Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
| ATE234830T1 (de) * | 1998-12-17 | 2003-04-15 | Hoffmann La Roche | 4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2 |
| US6239141B1 (en) | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
| PT1233943E (pt) * | 1999-11-24 | 2011-09-01 | Sugen Inc | Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres |
| ATE369359T1 (de) * | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| US6316672B1 (en) | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
| HRP20040112B1 (en) | 2001-08-15 | 2012-03-31 | Pharmacia & Upjohn Company | Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
| CN101983195A (zh) | 2008-02-21 | 2011-03-02 | 基因里克斯(英国)有限公司 | 新型多晶型物及其制备方法 |
| WO2009156837A2 (en) | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
-
2002
- 2002-08-13 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/en not_active Ceased
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/en not_active Expired - Lifetime
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/en not_active Expired - Lifetime
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko not_active Expired - Lifetime
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Ceased
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/en not_active Expired - Lifetime
- 2002-08-13 CA CA002455050A patent/CA2455050C/en not_active Expired - Lifetime
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
-
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
-
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
-
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20040029A7 (es) | Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen | |
| RU2009102252A (ru) | Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с | |
| CO5390079A1 (es) | Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina | |
| SE0202463D0 (sv) | Novel compounds | |
| EA201100482A1 (ru) | Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| RU2008139905A (ru) | Фармацевтическая композиция для наружного применения | |
| UY29182A1 (es) | "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones" | |
| AR029570A1 (es) | Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| RU2009121756A (ru) | Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk) | |
| AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| PE20212323A1 (es) | Formulaciones farmaceuticas | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
| RU2008105304A (ru) | Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы | |
| AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| RU2008106754A (ru) | Предотвращающий преждевременную овуляцию агент | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |